C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Bacterial lipopolysaccharide induction of IL-6 in rat telencephalic cells is mediated in part by IL-1.
TL;DR: It appeared reasonable to postulate that the effects of LPS on IL-6 production were mediated through IL-1 induction, and it was found that the inhibitory effect ofIL-1Ra was not significantly greater even when used at a concentration of 5,000 ng/ml.
Journal Article
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.
H Tilg,Leland Shapiro,Edouard Vannier,Debra D. Poutsiaka,Elizabeth Trehu,Michael B. Atkins,Charles A. Dinarello,James W. Mier +7 more
TL;DR: The results suggest that the amount of IL-1ra generated in response to IL-2 is most likely sufficient to down-modulate the production of proinflammatory cytokines.
Journal ArticleDOI
Interleukin-1α as an intracellular alarmin in cancer biology.
Journal ArticleDOI
The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.
Anne Sofie Høgh Kølbæk Kjær,Christel R. Brinkmann,Charles A. Dinarello,Rikke Olesen,Lars Østergaard,Ole S. Søgaard,Martin Tolstrup,Thomas A Rasmussen +7 more
TL;DR: Data indicate that panobinostat may have therapeutic potential to target excess inflammation in HIV patients with high cardiovascular risk and suppression of cardiovascular risk biomarkers was associated with a prominent reduction in the expression of genes related to inflammation and atherosclerosis.
Journal ArticleDOI
Interleukin-1 receptor antagonist: an index of dialysis-induced interleukin-1 production.
TL;DR: The results suggest that in dialysis patients, the endogenous production of IL-1Ra is a 'footprint' ofIL-1 beta production and can probably be used as a marker of the level of production of interleukin-1.